Precision epidemiology informing the drug development lifecycle.

Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.

Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.

Research and DevelopmentDetermining disease prevalence to establish development priorities.
 
Clinical TrialsDefining the most relevant patient groups to include in trials.
 
Market AccessGenerating disease burden studies to support HEOR teams with reimbursement and market access.
Market ExpansionDemonstrating the impact of new therapies on public health, and quantifying the impact of interventions.
Patient AdvocacyHighlighting unmet needs, and helping patient education campaigns raise awareness.

From molecule to market, our solutions can help.

 

Helping you at every stage

From informing early-stage R&D decisions through to market access and launch, view our solutions to find out how our data-driven epidemiology can support your product development, strategic planning and portfolio management.

Solutions

Why Us?

Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.

Why Us?

How do we do it?

We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.

Solutions

Whats our Track Record?

We’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.

Track Record

WHO’S BEHIND IT?

Our experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.

About Us

HealthLumen Blog

HealthLumen modelling study for Nesta identifies the government interventions needed to halve obesity in the UK over five years

Study highlights which health policies are most likely to be effective in decreasing the prevalence of obesity, with fiscal policies expected to be particularly cost beneficial. This research has informed Nesta’s digital Blueprint tool – which provides data on the health, economic, and feasibility impacts of various obesity interventions – aligning with Nesta’s mission of halving obesity rates in the UK by 2030.

Read

Join HealthLumen at key upcoming rare disease conferences in Q4 2024 

HealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences in the final quarter of this year.

Read

NEWS: New research identifying the number of women at risk of FNAIT to be presented at ASHG 2024

Rallybio, a clinical-stage biotechnology company, will be presenting the findings of a genetic database analysis study conducted in partnership with HealthLumen on Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) risk across racially and ethnically diverse populations at the American Society of Human Genetics (ASHG) 2024 Annual Meeting. The conference will take place from November 5–9 2024 in Denver, Colorado.

Read

Genomics and precision medicine: The new frontier for microsimulation

“Genomics requires a form of modelling that can capture individual genetic differences and responses to therapy – a purpose to which microsimulation is eminently suited.”

This quote, from a seminal review paper by Professors Deborah Schofield and Rupendra Shrestha of Macquarie University, pioneers in applying microsimulation techniques for modelling the costs and benefits of genomic medicine, formed the basis for a fascinating recent discussion with the HealthLumen team, on the role of microsimulation modelling techniques in precision medicine.

Read